Boston Scientific (NYSE:BSX) managed to stage a partial rebound on Friday, closing at $50.37 after a 2.03% gain. The recovery, however, only recouped 38% of the previous session's steep drop, leaving the stock with a 2.82% weekly loss. Trading volume was notably heavy at 31.8 million shares, exceeding the three-month average by 51.8%, a sign of heightened investor activity during the rebound.
The stock's intraday range was wide, opening at $49.22 and climbing as much as 3.41% before settling 1.04% below the day's peak of $50.90. By the close, the company's market capitalization stood at approximately $73.0 billion, adding about $1.45 billion in equity value on the day.
Weekly Performance Recap
Boston Scientific's share price has been volatile over the past week. The stock opened at $51.83 on August 14, then slipped to $51.43 on August 17, a 0.77% decline. It continued lower on August 18, losing 1.87% to $50.47, before a midweek rebound of 3.05% to $52.01. However, Thursday's 5.08% drop to $49.37 marked the steepest decline of the week, and Friday's gain was insufficient to offset that loss.
Fundamental Strength vs. Share Price Weakness
Despite the recent share price weakness, the company's underlying fundamentals remain solid. In the second quarter, Boston Scientific reported net sales of $5.442 billion, a 7.5% increase year-over-year. Adjusted earnings per share came in at $0.86, beating the company's guidance of $0.82 to $0.84. On a GAAP basis, EPS rose 15.1% to $0.61.
Revenue growth was driven by the Cardiovascular segment, which saw an 8.3% increase to $3.624 billion, while the MedSurg segment grew 5.9% to $1.818 billion. Chief Executive Mike Mahoney noted, "Our team delivered a solid quarter while continuing to navigate a dynamic environment." The company also executed a $2 billion accelerated share repurchase, retiring approximately 40 million shares.
Guidance Cut and Competitive Pressures
However, management lowered its full-year adjusted EPS guidance to $3.28–$3.32, down from previous expectations. The revision reflects weaker demand for the WATCHMAN device and increased competition in the U.S. electrophysiology market, which are expected to impact performance in the second half of the year.
Analyst Sentiment and Price Targets
Wall Street remains cautiously optimistic. According to S&P Global data compiled by StockAnalysis, 26 out of 31 analysts rate the stock as Buy or Strong Buy, down from 34 out of 34 in March. The number of Hold ratings increased from zero to five over the same period. Jefferies analyst Matthew Taylor maintained a Buy rating with a price target of $60. The consensus target stands at $62.69, implying a 24.46% upside from current levels, with a median target of $60 and a range of $44 to $94.
Upcoming Catalysts and Risks
Investors are now looking ahead to the company's planned $14.5 billion acquisition of Penumbra (NYSE:PEN). The deal is expected to dilute adjusted EPS by $0.06–$0.08 in the first full year after closing, but should become neutral or modestly accretive by the second year. The next test for the stock will come on Monday, when trading volumes could indicate whether the $50 level can hold. Any news on Penumbra's financing or regulatory approvals will likely have a greater impact than a single-day rally.
Key risks include slower WATCHMAN adoption, intensifying competition in U.S. electrophysiology, and potential dilution from the acquisition. Conversely, stronger product uptake or smoother integration of Penumbra could accelerate the stock's recovery. Boston Scientific is scheduled to report its next earnings on October 28, which will provide further clarity on these issues.
